Nectin-4 in bladder cancer: biology and predictive biomarker potential.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced bladder cancer, with a focus on its role as a therapeutic target and predictive biomarker
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[SUMMARY] Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[PURPOSE OF REVIEW] This review aims to summarize the biology and clinical relevance of Nectin-4 in patients with advanced bladder cancer, with a focus on its role as a therapeutic target and predicti
APA
Roessler N, Miszczyk M, et al. (2026). Nectin-4 in bladder cancer: biology and predictive biomarker potential.. Current opinion in urology, 36(1), 119-122. https://doi.org/10.1097/MOU.0000000000001354
MLA
Roessler N, et al.. "Nectin-4 in bladder cancer: biology and predictive biomarker potential.." Current opinion in urology, vol. 36, no. 1, 2026, pp. 119-122.
PMID
41182170 ↗
Abstract 한글 요약
[PURPOSE OF REVIEW] This review aims to summarize the biology and clinical relevance of Nectin-4 in patients with advanced bladder cancer, with a focus on its role as a therapeutic target and predictive biomarker.
[RECENT FINDINGS] Nectin-4 is consistently overexpressed in advanced bladder cancer, facilitating tumor progression and survival signaling. Its cell surface localization makes it an ideal target for antibody-drug conjugates (ADCs), such as enfortumab vedotin, which has shown excellent efficacy in both first-line treatment, post platinum-based chemotherapy, and following immune checkpoint inhibitors. Recent insights highlight Nectin-4 as potential predictive biomarker and a target for advanced medical imaging strategies. Resistance mechanisms and new combination approaches are currently being investigated.
[SUMMARY] Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
[RECENT FINDINGS] Nectin-4 is consistently overexpressed in advanced bladder cancer, facilitating tumor progression and survival signaling. Its cell surface localization makes it an ideal target for antibody-drug conjugates (ADCs), such as enfortumab vedotin, which has shown excellent efficacy in both first-line treatment, post platinum-based chemotherapy, and following immune checkpoint inhibitors. Recent insights highlight Nectin-4 as potential predictive biomarker and a target for advanced medical imaging strategies. Resistance mechanisms and new combination approaches are currently being investigated.
[SUMMARY] Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis.
- [Artificial urinary sphincter: contemporary overview of evidence, long-term outcomes, and clinical practice].
- Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.
- Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and -analysis of randomised controlled trials.
- Treatment of biochemical recurrence after primary therapy with curative intent.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.